Kenji Mamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kenji Mamoto has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Tadashi Okano
Center for Senile Degenerative Disorders (CSDD), Osaka Metropolitan University Graduate School of Medicine , Osaka
8 shared publications - Kentaro Inui
Department of Orthopaedic Surgery, Osaka Saiseikai Nakatsu HospitalOsaka, Japan
4 shared publications - Tatsuya Koike
Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare , Wakayama
4 shared publications - Yutaro Yamada
Center for Senile Degenerative Disorders (CSDD), Osaka Metropolitan University Graduate School of Medicine , Osaka
4 shared publications - Masahiro Tada
Department of Orthopaedic Surgery, Osaka City General Hospital, Osaka, Japan
3 shared publications - Xiaojuan Li
Cleveland Clinic, USA
3 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (6)
Comparative effectiveness and safety of sarilumab vs JAK inhibitors in late- and younger-onset rheumatoid arthritis
Objectives: Glucocorticoid (GC)- and MTX-sparing strategies are clinically important in RA, yet comparative real-world evidence for sarilumab (SAR) vs Janus kinase inhibitors (JAKi) is limited. Whether treatment effects differ by age at onset—late-onset RA (LORA) vs young-onset RA (YORA)—also remains unclear. This study aimed to compare the effectiveness and safety of SAR and JAKi in patients with LORA and YORA. Methods: We conducted a multicentre real-world cohort study of adults with RA initiating SAR or a JAKi. Outcomes over 12 months included change from baseline in MTX dose (ΔMTX, mg/week) and GC dose (ΔGC, mg/day), cumulative treatment discontinuation and change in Clinical Disease Activity Index (CDAI). Analyses were performed within LORA and YORA strata, and propensity score matching (PSM) was applied separately in each stratum to balance baseline characteristics. Sensitivity analyses were conducted in the matched cohorts. Results: Both SAR and JAKi were associated with progressive tapering of concomitant MTX and GC during follow-up. SAR was associated with a higher frequency of MTX discontinuation compared with JAKi. In contrast, GC discontinuation and CDAI improvement were broadly similar between treatments across age strata and MTX subgroups. Findings were consistent after PSM and in sensitivity analyses within both LORA and YORA. Conclusion: In routine clinical practice, SAR and JAKi support de-escalation of concomitant therapy. SAR may permit earlier MTX withdrawal without loss of disease control, with comparable GC tapering and disease activity improvement in both LORA and YORA.
- 3 June 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (6)
Open AccessComparative effectiveness and safety of sarilumab vs JAK inhibitors in late- and younger-onset rheumatoid arthritis
Objectives: Glucocorticoid (GC)- and MTX-sparing strategies are clinically important in RA, yet comparative real-world evidence for sarilumab (SAR) vs Janus kinase inhibitors (JAKi) is limited. Whether treatment effects differ by age at onset—late-onset RA (LORA) vs young-onset RA (YORA)—also remains unclear. This study aimed to compare the effectiveness and safety of SAR and JAKi in patients with LORA and YORA. Methods: We conducted a multicentre real-world cohort study of adults with RA initiating SAR or a JAKi. Outcomes over 12 months included change from baseline in MTX dose (ΔMTX, mg/week) and GC dose (ΔGC, mg/day), cumulative treatment discontinuation and change in Clinical Disease Activity Index (CDAI). Analyses were performed within LORA and YORA strata, and propensity score matching (PSM) was applied separately in each stratum to balance baseline characteristics. Sensitivity analyses were conducted in the matched cohorts. Results: Both SAR and JAKi were associated with progressive tapering of concomitant MTX and GC during follow-up. SAR was associated with a higher frequency of MTX discontinuation compared with JAKi. In contrast, GC discontinuation and CDAI improvement were broadly similar between treatments across age strata and MTX subgroups. Findings were consistent after PSM and in sensitivity analyses within both LORA and YORA. Conclusion: In routine clinical practice, SAR and JAKi support de-escalation of concomitant therapy. SAR may permit earlier MTX withdrawal without loss of disease control, with comparable GC tapering and disease activity improvement in both LORA and YORA.
- Open Access
- 2 January 2026
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 28 (1)
Real-world comparative effectiveness of sarilumab versus Janus kinase inhibitors as monotherapy in rheumatoid arthritis
Background: Sarilumab (SAR), an interleukin-6 receptor inhibitor (IL-6Ri), and Janus kinase inhibitors (JAKi) are approved options for rheumatoid arthritis (RA) when methotrexate (MTX) cannot be used. Real-world evidence for MTX-free monotherapy remains limited. Methods: We conducted a multicenter retrospective cohort study of RA patients receiving SAR or JAKi as MTX-free monotherapy. To reduce confounding, 1:1 propensity score matching was performed in the overall cohort ( n = 252, 126 per group) and separately within treatment-line strata: Phase 2 first-line biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs: 45 per group), Phase 3 second-line b/tsDMARDs (53 per group), and Phase 3 ≥ third-line b/tsDMARDs (47 per group). Outcomes over 12 months included drug retention, change in Clinical Disease Activity Index (CDAI), glucocorticoid (GC) tapering and discontinuation, low disease activity (LDA, CDAI ≤ 10), and safety profiles. Predictors of LDA were evaluated with logistic regression. This multicenter real-world. Results: Across matched strata by prior b/tsDMARDs, retention and CDAI change did not differ significantly between SAR and JAKi through 12 months. When classified by cause, adverse events (AEs)-related discontinuation was higher with JAKi, yielding lower AE-specific retention. Both groups demonstrated GC sparing overtime, with a greater increase in GC discontinuation for SAR than for JAKi in Phase 2. Baseline predictors of achieving LDA at 12 months included higher C-reactive protein (CRP) and platelet count (Plt) in both groups, with additional associations of younger age and lower hemoglobin (Hb) in the SAR. In safety analyses, overall AEs were less frequent with SAR than with JAKi, driven by lower risks of infection including herpes zoster, while other categories were similarly infrequent. Conclusion: SAR and JAKi showed no statistically significant differences in 12-month retention or disease control in MTX-free monotherapy settings. Higher CRP and Plt with lower Hb, particularly in younger patients, identified better response to SAR and support biomarker guided selection between IL-6Ri and JAKi. In Phase 2, GC discontinuation with SAR suggests a practical strategy to reduce AEs while maintaining efficacy. Prospective studies should validate these findings and define actionable thresholds.
- 2 January 2026
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 28 (1)
Open AccessReal-world comparative effectiveness of sarilumab versus Janus kinase inhibitors as monotherapy in rheumatoid arthritis
Background: Sarilumab (SAR), an interleukin-6 receptor inhibitor (IL-6Ri), and Janus kinase inhibitors (JAKi) are approved options for rheumatoid arthritis (RA) when methotrexate (MTX) cannot be used. Real-world evidence for MTX-free monotherapy remains limited. Methods: We conducted a multicenter retrospective cohort study of RA patients receiving SAR or JAKi as MTX-free monotherapy. To reduce confounding, 1:1 propensity score matching was performed in the overall cohort ( n = 252, 126 per group) and separately within treatment-line strata: Phase 2 first-line biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs: 45 per group), Phase 3 second-line b/tsDMARDs (53 per group), and Phase 3 ≥ third-line b/tsDMARDs (47 per group). Outcomes over 12 months included drug retention, change in Clinical Disease Activity Index (CDAI), glucocorticoid (GC) tapering and discontinuation, low disease activity (LDA, CDAI ≤ 10), and safety profiles. Predictors of LDA were evaluated with logistic regression. This multicenter real-world. Results: Across matched strata by prior b/tsDMARDs, retention and CDAI change did not differ significantly between SAR and JAKi through 12 months. When classified by cause, adverse events (AEs)-related discontinuation was higher with JAKi, yielding lower AE-specific retention. Both groups demonstrated GC sparing overtime, with a greater increase in GC discontinuation for SAR than for JAKi in Phase 2. Baseline predictors of achieving LDA at 12 months included higher C-reactive protein (CRP) and platelet count (Plt) in both groups, with additional associations of younger age and lower hemoglobin (Hb) in the SAR. In safety analyses, overall AEs were less frequent with SAR than with JAKi, driven by lower risks of infection including herpes zoster, while other categories were similarly infrequent. Conclusion: SAR and JAKi showed no statistically significant differences in 12-month retention or disease control in MTX-free monotherapy settings. Higher CRP and Plt with lower Hb, particularly in younger patients, identified better response to SAR and support biomarker guided selection between IL-6Ri and JAKi. In Phase 2, GC discontinuation with SAR suggests a practical strategy to reduce AEs while maintaining efficacy. Prospective studies should validate these findings and define actionable thresholds.
- Open Access
- 3 February 2025
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 32 (3) , 182-189
Change of autoantibody levels in established rheumatoid arthritis patients treated by biological disease-modifying anti-rheumatic drugs -the AIRTIGHT study-
Shohei Anno, M.D., Kentaro Inui, M.D., Ph.D., Masahiro Tada, M.D., Ph.D., Yuko Sugioka, M.D., Ph.D., Tadashi Okano, M.D., Ph.D.,, Kenji Mamoto, M.D., Ph.D., Tatsuya Koike, M.D., Ph.D.. J Rheum Dis 2025;32:182-9. https://doi.org/10.4078/jrd.2024.0130
- 3 February 2025
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 32 (3) , 182-189
Open AccessChange of autoantibody levels in established rheumatoid arthritis patients treated by biological disease-modifying anti-rheumatic drugs -the AIRTIGHT study-
Shohei Anno, M.D., Kentaro Inui, M.D., Ph.D., Masahiro Tada, M.D., Ph.D., Yuko Sugioka, M.D., Ph.D., Tadashi Okano, M.D., Ph.D.,, Kenji Mamoto, M.D., Ph.D., Tatsuya Koike, M.D., Ph.D.. J Rheum Dis 2025;32:182-9. https://doi.org/10.4078/jrd.2024.0130
- Open Access
- 2 December 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (23) , 7321
Immune Response to an Adjuvanted Recombinant Zoster Vaccine in Japanese Patients with Rheumatoid Arthritis Receiving Upadacitinib (End Zoster-J Study): Study Protocol for an Exploratory Parallel Triple-Arm Prospective Trial
Background: Janus kinase (JAK) inhibitors have emerged as a new class of disease-modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis (RA). However, herpes zoster is one of the common adverse events of JAK inhibitors, including upadacitinib, which is especially high in Japanese patients with RA compared to those from Western countries. Recombinant zoster vaccine (Shingrix®) is an adjuvanted subunit vaccine containing varicella-zoster virus (VZV) glycoprotein E (gE) that is effective in adults over 50 years of age. Despite this, no studies have examined its immunogenicity in Japanese patients receiving upadacitinib. Therefore, this study aims to examine the effectiveness of the recombinant zoster vaccine in Japanese patients with RA receiving upadacitinib. Methods: This is a single-center, exploratory, interventional, open-label, parallel triple-arm, prospective study. A total of 69 patients (23 in each group) aged 50 years or over and treated with a stable dose of methotrexate (MTX) monotherapy (6–12 mg/week), upadacitinib monotherapy (15 mg/day), or MTX (6–12 mg/week) + upadacitinib 15 mg/day (combination) for at least 1 month prior to study entry will be included. Moreover, all three groups will receive two intramuscular injections of the recombinant zoster vaccine at 8-week intervals. The primary endpoint is the proportion of positive anti-gE antibodies 4 weeks after the second injection. Secondary endpoints include RA disease activity, positive gE-specific CD4+ T-cells, and VZV-specific antibodies at indicated time points. Data on outcome measures will be collected at baseline and at 4, 8, 12, and 20 weeks. Endpoints will be summarized using descriptive statistics from baseline therapy, and results will be compared in an exploratory manner. Discussion: Despite the limited generalizability due to its design as a single-center, single-ethnic study, small sample size, and short observation period, this study provides evidence on the effectiveness and tolerability of recombinant zoster vaccine in Japanese patients with RA receiving upadacitinib.
- 2 December 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (23) , 7321
Open AccessImmune Response to an Adjuvanted Recombinant Zoster Vaccine in Japanese Patients with Rheumatoid Arthritis Receiving Upadacitinib (End Zoster-J Study): Study Protocol for an Exploratory Parallel Triple-Arm Prospective Trial
Background: Janus kinase (JAK) inhibitors have emerged as a new class of disease-modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis (RA). However, herpes zoster is one of the common adverse events of JAK inhibitors, including upadacitinib, which is especially high in Japanese patients with RA compared to those from Western countries. Recombinant zoster vaccine (Shingrix®) is an adjuvanted subunit vaccine containing varicella-zoster virus (VZV) glycoprotein E (gE) that is effective in adults over 50 years of age. Despite this, no studies have examined its immunogenicity in Japanese patients receiving upadacitinib. Therefore, this study aims to examine the effectiveness of the recombinant zoster vaccine in Japanese patients with RA receiving upadacitinib. Methods: This is a single-center, exploratory, interventional, open-label, parallel triple-arm, prospective study. A total of 69 patients (23 in each group) aged 50 years or over and treated with a stable dose of methotrexate (MTX) monotherapy (6–12 mg/week), upadacitinib monotherapy (15 mg/day), or MTX (6–12 mg/week) + upadacitinib 15 mg/day (combination) for at least 1 month prior to study entry will be included. Moreover, all three groups will receive two intramuscular injections of the recombinant zoster vaccine at 8-week intervals. The primary endpoint is the proportion of positive anti-gE antibodies 4 weeks after the second injection. Secondary endpoints include RA disease activity, positive gE-specific CD4+ T-cells, and VZV-specific antibodies at indicated time points. Data on outcome measures will be collected at baseline and at 4, 8, 12, and 20 weeks. Endpoints will be summarized using descriptive statistics from baseline therapy, and results will be compared in an exploratory manner. Discussion: Despite the limited generalizability due to its design as a single-center, single-ethnic study, small sample size, and short observation period, this study provides evidence on the effectiveness and tolerability of recombinant zoster vaccine in Japanese patients with RA receiving upadacitinib.
- Open Access
- 30 September 2024
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 39 (3) , 350-357
Comparison of creatine kinase elevation caused by Janus kinase inhibitors and interleukin-6 inhibitors in patients with rheumatoid arthritis: A propensity score-matched study
Objectives: This study aimed to examine whether creatine kinase (CK) elevation occurs with interleukin (IL)-6 inhibitors, as in Janus kinase (JAK) inhibitors, which are reported to increase CK levels in rheumatoid arthritis. Patients and methods: A multicenter database of JAK inhibitor and IL-6 inhibitor treatment was retrospectively searched between January 2016 to December 2022; 142 cases (117 females, 25 males, mean age: 63.8±13.0 years; range, 20 to 85 years), with 71 cases in each group, were extracted by propensity score matching using age, sex, body mass index, and CK at 0 weeks. The outlier rate was compared. Patients’ background characteristics related to elevated CK levels at 24 weeks were investigated by univariate and multivariate analyses. Results: Creatine kinase levels at 4 and 12 weeks were significantly higher with JAK inhibitors than with IL-6 inhibitors (four weeks, 72 vs. 87.5 IU/mL, p=0.016; 12 weeks, 71 vs. 95.5 IU/mL, p=0.028). The outlier rate (Grade 1) with JAK inhibitors increased significantly over time (0 weeks, 4.2%; four weeks, 18.1%; 12 weeks, 21.7%; 24 weeks, 18.3%; p=0.015), whereas that with IL-6 inhibitors increased slightly (0 weeks, 5.6%; four weeks, 9.2%; 12 weeks, 8.6%; 24 weeks, 8.5%; p=0.745), with a significant difference between the groups (p=0.035). No patients discontinued treatment due to myalgia or renal dysfunction. The factors significantly positively related to elevated CK levels at 24 weeks were male sex and creatinine. Those significantly negatively related were Steinbrocker stage and class, modified health assessment questionnaire scores, estimated glomerular filtration rate, and glucocorticoid dose. Conclusion: Mild CK elevations with JAK inhibitors are not a particular clinical problem. CK elevation might be specific to JAK inhibitors.
- 30 September 2024
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 39 (3) , 350-357
Open AccessComparison of creatine kinase elevation caused by Janus kinase inhibitors and interleukin-6 inhibitors in patients with rheumatoid arthritis: A propensity score-matched study
Objectives: This study aimed to examine whether creatine kinase (CK) elevation occurs with interleukin (IL)-6 inhibitors, as in Janus kinase (JAK) inhibitors, which are reported to increase CK levels in rheumatoid arthritis. Patients and methods: A multicenter database of JAK inhibitor and IL-6 inhibitor treatment was retrospectively searched between January 2016 to December 2022; 142 cases (117 females, 25 males, mean age: 63.8±13.0 years; range, 20 to 85 years), with 71 cases in each group, were extracted by propensity score matching using age, sex, body mass index, and CK at 0 weeks. The outlier rate was compared. Patients’ background characteristics related to elevated CK levels at 24 weeks were investigated by univariate and multivariate analyses. Results: Creatine kinase levels at 4 and 12 weeks were significantly higher with JAK inhibitors than with IL-6 inhibitors (four weeks, 72 vs. 87.5 IU/mL, p=0.016; 12 weeks, 71 vs. 95.5 IU/mL, p=0.028). The outlier rate (Grade 1) with JAK inhibitors increased significantly over time (0 weeks, 4.2%; four weeks, 18.1%; 12 weeks, 21.7%; 24 weeks, 18.3%; p=0.015), whereas that with IL-6 inhibitors increased slightly (0 weeks, 5.6%; four weeks, 9.2%; 12 weeks, 8.6%; 24 weeks, 8.5%; p=0.745), with a significant difference between the groups (p=0.035). No patients discontinued treatment due to myalgia or renal dysfunction. The factors significantly positively related to elevated CK levels at 24 weeks were male sex and creatinine. Those significantly negatively related were Steinbrocker stage and class, modified health assessment questionnaire scores, estimated glomerular filtration rate, and glucocorticoid dose. Conclusion: Mild CK elevations with JAK inhibitors are not a particular clinical problem. CK elevation might be specific to JAK inhibitors.
- 17 September 2022
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 52, 353-359
Impact of disease burden or inflammation on nutritional assessment by the GLIM criteria in female patients with rheumatoid arthritis
- 17 September 2022
- Published by Elsevier in Clinical Nutrition ESPEN
- Vol. 52, 353-359
Impact of disease burden or inflammation on nutritional assessment by the GLIM criteria in female patients with rheumatoid arthritis
- Open Access
- 1 September 2020
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 10 (9) , 1748-1762
Diagnostic interchangeability of deep convolutional neural networks reconstructed knee MR images: preliminary experience
Background: MRI acceleration using deep learning (DL) convolutional neural networks (CNNs) is a novel technique with great promise. Increasing the number of convolutional layers may allow for more accurate image reconstruction. Studies on evaluating the diagnostic interchangeability of DL reconstructed knee magnetic resonance (MR) images are scarce. The purpose of this study was to develop a deep CNN (DCNN) with an optimal number of layers for accelerating knee magnetic resonance imaging (MRI) acquisition by 6-fold and to test the diagnostic interchangeability and image quality of nonaccelerated images versus images reconstructed with a 15-layer DCNN or 3-layer CNN. Methods: For the feasibility portion of this study, 10 patients were randomly selected from the Osteoarthritis Initiative (OAI) cohort. For the interchangeability portion of the study, 40 patients were randomly selected from the OAI cohort. Three readers assessed meniscal and anterior cruciate ligament (ACL) tears and cartilage defects using DCNN, CNN, and nonaccelerated images. Image quality was subjectively graded as nondiagnostic, poor, acceptable, or excellent. Interchangeability was tested by comparing the frequency of agreement when readers used both accelerated and nonaccelerated images to frequency of agreement when readers only used nonaccelerated images. A noninferiority margin of 0.10 was used to ensure type I error ≤5% and power ≥80%. A logistic regression model using generalized estimating equations was used to compare proportions; 95% confidence intervals (CIs) were constructed. Results: DCNN and CNN images were interchangeable with nonaccelerated images for all structures, with excess disagreement values ranging from –2.5% [95% CI: (–6.1, 1.1)] to 3.0% [95% CI: (–0.1, 6.1)]. The quality of DCNN images was graded higher than that of CNN images but less than that of nonaccelerated images [excellent/acceptable quality: DCNN, 95% of cases (114/120); CNN, 60% (72/120); nonaccelerated, 97.5% (117/120)]. Conclusions: Six-fold accelerated knee images reconstructed with a DL technique are diagnostically interchangeable with nonaccelerated images and have acceptable image quality when using a 15-layer CNN.
- 1 September 2020
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 10 (9) , 1748-1762
Open AccessDiagnostic interchangeability of deep convolutional neural networks reconstructed knee MR images: preliminary experience
Background: MRI acceleration using deep learning (DL) convolutional neural networks (CNNs) is a novel technique with great promise. Increasing the number of convolutional layers may allow for more accurate image reconstruction. Studies on evaluating the diagnostic interchangeability of DL reconstructed knee magnetic resonance (MR) images are scarce. The purpose of this study was to develop a deep CNN (DCNN) with an optimal number of layers for accelerating knee magnetic resonance imaging (MRI) acquisition by 6-fold and to test the diagnostic interchangeability and image quality of nonaccelerated images versus images reconstructed with a 15-layer DCNN or 3-layer CNN. Methods: For the feasibility portion of this study, 10 patients were randomly selected from the Osteoarthritis Initiative (OAI) cohort. For the interchangeability portion of the study, 40 patients were randomly selected from the OAI cohort. Three readers assessed meniscal and anterior cruciate ligament (ACL) tears and cartilage defects using DCNN, CNN, and nonaccelerated images. Image quality was subjectively graded as nondiagnostic, poor, acceptable, or excellent. Interchangeability was tested by comparing the frequency of agreement when readers used both accelerated and nonaccelerated images to frequency of agreement when readers only used nonaccelerated images. A noninferiority margin of 0.10 was used to ensure type I error ≤5% and power ≥80%. A logistic regression model using generalized estimating equations was used to compare proportions; 95% confidence intervals (CIs) were constructed. Results: DCNN and CNN images were interchangeable with nonaccelerated images for all structures, with excess disagreement values ranging from –2.5% [95% CI: (–6.1, 1.1)] to 3.0% [95% CI: (–0.1, 6.1)]. The quality of DCNN images was graded higher than that of CNN images but less than that of nonaccelerated images [excellent/acceptable quality: DCNN, 95% of cases (114/120); CNN, 60% (72/120); nonaccelerated, 97.5% (117/120)]. Conclusions: Six-fold accelerated knee images reconstructed with a DL technique are diagnostically interchangeable with nonaccelerated images and have acceptable image quality when using a 15-layer CNN.
- 30 July 2020
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 28 (12) , 1539-1550
Multi-vendor multi-site T1ρ and T2 quantification of knee cartilage
- 30 July 2020
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 28 (12) , 1539-1550
Multi-vendor multi-site T1ρ and T2 quantification of knee cartilage
- 1 January 2020
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 28 (1) , 82-91
Infrapatellar fat pad abnormalities are associated with a higher inflammatory synovial fluid cytokine profile in young adults following ACL tear
- 1 January 2020
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 28 (1) , 82-91
Infrapatellar fat pad abnormalities are associated with a higher inflammatory synovial fluid cytokine profile in young adults following ACL tear
- 4 March 2019
- Published by Springer Nature in La radiologia medica
- Vol. 124 (11) , 1101-1111
Clinical utility and potential of ultrasound in osteoarthritis
Osteoarthritis (OA) is the most common disorder of human joints. Imaging is necessary in daily practice for OA patients, and conventional radiography remains the gold standard. However, conventional radiography is not sensitive in the early stage of OA and cannot clearly detect inflammatory condition. Recently, ultrasonography (US) is widely used in musculoskeletal field and US performs better or at least equally well for identification of osteophytes and morphologic degeneration of cartilage in OA patients. US provides relevant additional diagnostic information on pathologic changes in soft tissue (e.g., synovitis, meniscal injuries and Baker’s cysts) not depicted by conventional radiography. The advantage of US is its ability to visualize even in small and hidden morphologic change even in small joints. Thus, US may be a useful imaging technique for not only knee OA but also hand OA. This review article explains relevant pathologic findings in OA and clinical usefulness in daily practice with US images.
- 4 March 2019
- Published by Springer Nature in La radiologia medica
- Vol. 124 (11) , 1101-1111
Clinical utility and potential of ultrasound in osteoarthritis
Osteoarthritis (OA) is the most common disorder of human joints. Imaging is necessary in daily practice for OA patients, and conventional radiography remains the gold standard. However, conventional radiography is not sensitive in the early stage of OA and cannot clearly detect inflammatory condition. Recently, ultrasonography (US) is widely used in musculoskeletal field and US performs better or at least equally well for identification of osteophytes and morphologic degeneration of cartilage in OA patients. US provides relevant additional diagnostic information on pathologic changes in soft tissue (e.g., synovitis, meniscal injuries and Baker’s cysts) not depicted by conventional radiography. The advantage of US is its ability to visualize even in small and hidden morphologic change even in small joints. Thus, US may be a useful imaging technique for not only knee OA but also hand OA. This review article explains relevant pathologic findings in OA and clinical usefulness in daily practice with US images.